Biomarker-guided drug therapy
A patient-focused approach
Parallel to its therapeutic solutions, using a mechanism-based biomarker, Inotrem is working in collaboration with Roche Diagnostics on the establishment of a companion diagnostic tool in septic shock.
The rationale is to circumvent the high heterogeneity of septic shock patients’ population and identify those who are more likely to benefit from the nangibotide-based treatment currently under development at Inotrem.
Opening a new front in critical care medicine
The companion diagnostic test uses a soluble plasma circulating protein, the soluble form of the TREM-1 receptor. It is developed on the Roche proprietary Elecsys® platform. Soluble TREM-1 functions as a direct and reliable marker of the activation of the TREM-1 pathway and represent a mechanism-based biomarker. Measurement of sTREM-1 is a proven valuable indicator for the diagnosis and outcome prediction of septic shock patients.
The vision is to use the measurement of the blood concentration of the soluble form of the TREM-1 receptor to identify the patients who are more likely to respond to the treatment